Actinium Pharmaceuticals reports data from Phase III trial of AML treatment - MSN

Regeneron advances anticoagulant antibody pair to late-stage testing - FirstWord Pharma

Corcept's ALS drug trial disappoints, but zero deaths in high-dose group - FirstWord Pharma

Calquence Plus Venetoclax Shows Promise in Front-Line CLL Treatment

AstraZeneca's AMPLIFY Phase III trial reveals Calquence combined with venetoclax significantly improves progression-free survival in chronic lymphocytic leukemia (CLL) patients.
The Calquence plus venetoclax regimen reduced the risk of disease progression or death by 35% compared to standard chemoimmunotherapy.

Moleculin Biotech Accelerates Data Readout for Annamycin AML Trial

Moleculin Biotech amended its Phase 3 MIRACLE trial protocol for Annamycin, aiming for accelerated approval in relapsed/refractory AML.
The amended protocol allows unblinding of preliminary efficacy and safety data after the first 45 subjects, speeding up data availability.

Moleculin Biotech Accelerates Data Readout for Phase 3 AML Trial of Annamycin

Moleculin Biotech has amended its Phase 3 MIRACLE trial protocol for Annamycin in relapsed/refractory AML, potentially accelerating its approval timeline.
The amended protocol allows for unblinding of preliminary efficacy and safety data after the first 45 subjects, expected in H2 2025.

Otsuka reports data from Phase III Alzheimer's agitation trial - MSN

EC approves Daiichi Sankyo's Vanflyta for acute myeloid leukaemia - MSN

MSD terminates Phase II trials for Alzheimer's drug due to liver toxicity - MSN

Alder BioPharmaceuticals to Showcase Eptinezumab's Efficacy in Migraine Prevention at AHS Meeting

Alder BioPharmaceuticals announced the presentation of new data from the PROMISE 1 and PROMISE 2 phase 3 clinical trials for eptinezumab, their lead investigational product for migraine prevention, at the American Headache Society annual meeting. The data highlights eptinezumab's efficacy in reducing migraine days and improving quality of life for patients.

Alder BioPharmaceuticals to Present New Phase 3 Migraine Prevention Data for Eptinezumab

Alder BioPharmaceuticals announced it will present new Phase 3 data for eptinezumab, its lead investigational product for migraine prevention, at the 70th Annual American Academy of Neurology Meeting. The presentations will include data from the PROMISE 1 and PROMISE 2 clinical trials, highlighting eptinezumab's potential as a treatment option for migraine sufferers.